With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process
The field of antibody therapeutics is rapidly growing, with over 210 antibodies currently approved or in regulatory review and ~ 1,250 antibodies in clinical development. Antibodies are highly versatile molecules that, with strategic design of their antigen-binding domain (Fab) and the domain respon...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2453515 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832085537784070144 |
|---|---|
| author | Silvia Crescioli Shashi Jatiani Lenny Moise |
| author_facet | Silvia Crescioli Shashi Jatiani Lenny Moise |
| author_sort | Silvia Crescioli |
| collection | DOAJ |
| description | The field of antibody therapeutics is rapidly growing, with over 210 antibodies currently approved or in regulatory review and ~ 1,250 antibodies in clinical development. Antibodies are highly versatile molecules that, with strategic design of their antigen-binding domain (Fab) and the domain responsible for mediating effector functions (Fc), can be used in a wide range of therapeutic indications. Building on many years of progress, the biopharmaceutical industry is now advancing innovative research and development by exploring new targets and new formats and using antibody engineering to fine-tune functions tailored to specific disease requirements. In addition to considering the target and the disease context, however, the unique features of each therapeutic antibody trigger a diverse set of Fc-mediated effector functions. To avoid unexpected results on safety and efficacy outcomes during the later stages of the development process, it is crucial to measure the impact of antibody design on Fc-mediated effector function early in the antibody development process. Given the breadth of effector functions antibodies can deploy and the close interplay between the antibody Fab and Fc functional domains, it is important to conduct a comprehensive evaluation of Fc-mediated functions using an array of antigen-specific biophysical and cell-mediated functional assays. Here, we review antibody and Fc receptor properties that influence Fc effector functions and discuss their implications on development of safe and efficacious antibody therapeutics. |
| format | Article |
| id | doaj-art-a5019c14510a4fe79ad6a46212b93c8a |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-a5019c14510a4fe79ad6a46212b93c8a2025-02-06T16:10:15ZengTaylor & Francis GroupmAbs1942-08621942-08702025-12-0117110.1080/19420862.2025.2453515With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development processSilvia Crescioli0Shashi Jatiani1Lenny Moise2Independent Consultant, London, UKSeromYx Systems, Woburn, MA, USASeromYx Systems, Woburn, MA, USAThe field of antibody therapeutics is rapidly growing, with over 210 antibodies currently approved or in regulatory review and ~ 1,250 antibodies in clinical development. Antibodies are highly versatile molecules that, with strategic design of their antigen-binding domain (Fab) and the domain responsible for mediating effector functions (Fc), can be used in a wide range of therapeutic indications. Building on many years of progress, the biopharmaceutical industry is now advancing innovative research and development by exploring new targets and new formats and using antibody engineering to fine-tune functions tailored to specific disease requirements. In addition to considering the target and the disease context, however, the unique features of each therapeutic antibody trigger a diverse set of Fc-mediated effector functions. To avoid unexpected results on safety and efficacy outcomes during the later stages of the development process, it is crucial to measure the impact of antibody design on Fc-mediated effector function early in the antibody development process. Given the breadth of effector functions antibodies can deploy and the close interplay between the antibody Fab and Fc functional domains, it is important to conduct a comprehensive evaluation of Fc-mediated functions using an array of antigen-specific biophysical and cell-mediated functional assays. Here, we review antibody and Fc receptor properties that influence Fc effector functions and discuss their implications on development of safe and efficacious antibody therapeutics.https://www.tandfonline.com/doi/10.1080/19420862.2025.2453515ComplementcytotoxicityengineeringFc effector functionFc receptorphagocytosis |
| spellingShingle | Silvia Crescioli Shashi Jatiani Lenny Moise With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process mAbs Complement cytotoxicity engineering Fc effector function Fc receptor phagocytosis |
| title | With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process |
| title_full | With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process |
| title_fullStr | With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process |
| title_full_unstemmed | With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process |
| title_short | With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process |
| title_sort | with great power comes great responsibility the importance of broadly measuring fc mediated effector function early in the antibody development process |
| topic | Complement cytotoxicity engineering Fc effector function Fc receptor phagocytosis |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2025.2453515 |
| work_keys_str_mv | AT silviacrescioli withgreatpowercomesgreatresponsibilitytheimportanceofbroadlymeasuringfcmediatedeffectorfunctionearlyintheantibodydevelopmentprocess AT shashijatiani withgreatpowercomesgreatresponsibilitytheimportanceofbroadlymeasuringfcmediatedeffectorfunctionearlyintheantibodydevelopmentprocess AT lennymoise withgreatpowercomesgreatresponsibilitytheimportanceofbroadlymeasuringfcmediatedeffectorfunctionearlyintheantibodydevelopmentprocess |